Targeting UDP-galactopyranose mutases from eukaryotic human pathogens

Current Pharmaceutical Design

Volumn 19, Issue 14, 2013, Pages 2561-2573

  Kizjakina, Karina ^a   Tanner, John J ^b,c   Sobrado, Pablo ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c University of Missouri   (United States)

Author keywords

Enzyme drug target; Eukaryotic pathogens; Flavoenzyme; Galactofuranose; Galactopyranose; Inhibitors; Non redox reaction; UDP galactopyranose mutase

Indexed keywords

FURAN DERIVATIVE; GALACTOFURANOSE; GALACTOSE; ISOMERASE INHIBITOR; MUTASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GALACTOPYRANOSE MUTASE; URIDINE DIPHOSPHATE GALACTOPYRANOSE MUTASE INHIBITOR;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHAGAS DISEASE; CRYSTAL STRUCTURE; DEINOCOCCUS RADIODURANS; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; ENZYME KINETICS; ENZYME STRUCTURE; ESCHERICHIA COLI; HIGH THROUGHPUT SCREENING; HUMAN; KLEBSIELLA PNEUMONIAE; LEISHMANIA MAJOR; LEISHMANIASIS; MOLECULAR WEIGHT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TROPICAL DISEASE; TRYPANOSOMA CRUZI;

AMINO ACID SEQUENCE; ANIMALS; ASPERGILLOSIS; BACTERIA; BINDING SITES; DRUG DISCOVERY; ENZYME INHIBITORS; EUKARYOTA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTRAMOLECULAR TRANSFERASES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTOZOAN INFECTIONS; SEQUENCE ALIGNMENT; VIRULENCE;

EID: 84877808343     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319140007     Document Type: Review

References (101)

1. Clayton J. Chagas disease: pushing through the pipeline. Nature 2010; 465: S12-5.
2. Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 2011; 64(3): 606-8.
3. Chen C-K, Leung SSF, Guilbert C, et al. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis 2010; 4(4): e651.
4. Croft SL, Olliaro P. Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect 2011; 17(10): 1478-83.
5. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52(9): 1123-9.
6. Mellado E, Alcazar-Fuoli L, Garcia-Effron G, et al. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol 2006; 44: S367-71.
7. Savioli, L., and Daumerie, D. (2010) First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases (Crompton, D. W. T., Ed.) World Health Organization, Geneva.
8. Hotez PJ, Kamath A. Neglected Tropical Diseases in Sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009; 3(8): e412.
9. Kradin RL, Mark EJ. The pathology of pulmonary disorders due to Aspergillus spp. Arch Pathol Lab Med 2008; 132(4): 606-14.
10. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46(3): 327-60.
11. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47(9): 1176-84.
12. Duschak VG, Couto AS. An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Pat Antiinfect Drug Discov 2007; 2: 19-51.
13. Oppenheimer M, Valenciano AL, Sobrado P. Biosynthesis of galactofuranose in kinetoplastids: novel therapeutic targets for treating leishmaniasis and Chagas' disease. Enzyme Res 2011; 2011.
14. Pedersen LL, Turco SJ. Galactofuranose metabolism: a potential target for antimicrobial chemotherapy. Cell Mol Life Sci 2003; 60(2): 259-66.
15. Rassi Jr A, Rassi A, Marin-Neto JA. Chagas disease. The Lancet 2010; 375(9723): 1388-402.
16. Pereira KS, Schmidt FL, Guaraldo AMA, et al. Chagas' disease as a foodborne illness. J Food Prot 2009; 72(2): 441-6.
17. Rassi A, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease. Circulation 2007; 115(9): 1101-8.
18. Lima FM, Oliveira P, Mortara RA, Silveira JF, Bahia D. The challenge of Chagas' disease: has the human pathogen, Trypanosoma cruzi, learned how to modulate signaling events to subvert host cells? N Biotechnol 2010; 27(6): 837-43.
19. Leishman WB. On the possibility of the occurence of trypanosomiasis in India. BMJ 1903; 1(2213): 1252-4.
20. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5(11): 873-82.
21. Schmalhorst PS, Krappmann S, Vervecken W, et al. Contribution of galactofuranose to the virulence of the opportunistic pathogen Aspergillus fumigatus. Eukaryot Cell 2008; 7: 1268-77.
22. Damveld RA, Franken A, Arentshorst M, et al. A novel screening method for cell wall mutants in Aspergillus niger identifies UDPgalactopyranose mutase as an important protein in fungal cell wall biosynthesis. Genetics 2008; 178(2): 873-81.
23. Lamarre C, Beau R, Balloy V, et al. Galactofuranose attenuates cellular adhesion of Aspergillus fumigatus. Cell Microbiol 2009; 11(11): 1612-23.
24. Virnig C, Bush RK. Allergic bronchopulmonary aspergillosis: a US perspective. Curr Opin Pulm Med 2007; 13: 67-71.
25. Chong S, Lee KS, Yi CA, et al. Pulmonary fungal infection: imaging findings in immunocompetent and immunocompromised patients. Eur J Radiol 2006; 59(3): 371-83.
26. Chamilos G, Kontoyiannis DP. Defining the diagnosis of invasive aspergillosis. Med Mycol 2006; 44: S163-S72.
27. Dutkiewicz R, Hage CA. Aspergillus infections in the critically ill. Proc Am Thorac Soc 2010; 7(3): 204-9.
28. Zilberberg MD, Shorr AF. Fungal infections in the ICU. Infect Dis Clin North Am 2009; 23(3): 625-42.
29. Lai K, Elsas LJ, Wierenga KJ. Galactose toxicity in animals. IUBMB Life 2009; 61(11): 1063-74.
30. Frey P. The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. FASEB J 1996; 10(4): 461-70.
31. Isselbacher KJ. Evidence for an accessory pathway of galactose metabolism in mammalian liver. Science 1957; 126(3275): 652-4.
32. Almeida IC, Ferguson MAJ, Schenkman S, Travassos LR. GPIanchored glycoconjugates from Trypanosoma cruzi trypomastigotes are recognized by lytic anti--galactosyl antibodies isolated from patients with chronic Chagas' disease. Braz J Med Biol Res 1994; 27: 443-7.
33. Ralton JE, Milne KG, Guther MLS, Field RA, Ferguson MAJ. The mechanism of inhibition of glycosylphosphatidylinositol anchor biosynthesis in Trypanosoma brucei by mannosamine. J Biol Chem 1993; 268: 24183-9.
34. Turnock DC, Ferguson MAJ. Sugar nucleotide pools of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major. Eukaryot Cell 2007; 6(8): 1450-63.
35. MacRae JI, Obado SO, Turnock DC, et al. The suppression of galactose metabolism in Trypanosoma cruzi epimastigotes causes changes in cell surface molecular architecture and cell morphology. Mol Biochem Parasitol 2006; 147(1): 126-36.
36. Ferguson MAJ. The surface glycoconjugates of trypanosomatid parasites. Philos Trans R Soc Lond B Biol Sci 1997; 352: 1295-302.
37. Turner CW, Lima MF, Villalta F. Trypanosoma cruzi uses a 45-kDa mucin for adhesion to mammalian cells. Biochem Biophys Res Commun 2002; 290(1): 29-34.
38. de Lederkremer RM, Colli W. Galactofuranose-containing glycoconjugates in trypanosomatids. Glycobiology 1995; 5(6): 547-52.
39. Spath GF, Garraway LA, Turco SJ, Beverley SM. The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci 2003; 100: 9536-41.
40. Zhang K, Barron T, Turco SJ, Beverley SM. The LPG1 gene family of Leishmania major. Mol Biochem Parasitol 2004; 136: 11-23.
41. Suzuki E, Tanaka AK, Toledo MS, Takahashi HK, Straus AH. Role of β-D-galactofuranose in Leishmania major macrophage invasion. Infect Immun 2002; 70(12): 6592-6.
42. Suzuki E, Tanaka AK, Toledo MS, et al. Trypanosomatid and fungal glycolipids and sphingolipids as infectivity factors and potential targets for development of new therapeutic strategies. Biochim Biophys Acta 2008; 1780(3): 362-9.
43. Pattron DD. Aspergillus, health implication & recommendations for public health food safety. Internet J Food Safety 2006; 8: 19-23.
44. Tefsen B, Ram AFJ, van Die I, Routier FH. Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact. Glycobiology 2011.
45. Leitão EA, Bittencourt VCB, Haido RMT, et al. β-Galactofuranose-containing O-linked oligosaccharides present in the cell wall peptidogalactomannan of Aspergillus fumigatus contain immunodominant epitopes. Glycobiology 2003; 13(10): 681-92.
46. Simenel C, Coddeville B, Delepierre M, Latgé J-P, Fontaine T. Glycosylinositolphosphoceramides in Aspergillus fumigatus. Glycobiology 2008; 18(1): 84-96.
47. Costachel C, Coddeville B, Latgé J-P, Fontaine T. Glycosylphosphatidylinositol-anchored fungal polysaccharide in Aspergillus fumigatus. J Biol Chem 2005; 280(48): 39835-42.
48. Beauvais A, Maubon D, Park S, et al. Two (1-3) glucan synthases with different functions in Aspergillus fumigatus. Appl Environ Microbiol 2005; 71(3): 1531-8.
49. El-Ganiny AM, Sheoran I, Sanders DAR, Kaminskyj SGW. Aspergillus nidulans UDP-glucose-4-epimerase UgeA has multiple roles in wall architecture, hyphal morphogenesis, and asexual development. Fungal Genet Biol 2010; 47(7): 629-35.
50. Miller SM. A new role for an old cofactor. Nat Struct Mol Biol 2004; 11(6): 497-8.
51. Bornemann S. Flavoenzymes that catalyse reactions with no net redox change. Nat Prod Rep 2002; 19: 761-72.
52. Richards MR, Lowary TL. Chemistry and biology of galactofuranose-containing polysaccharides. Chembiochem 2009; 10(12): 1920-38.
53. Stevenson G, Andrianopoulos K, Hobbs M, Reeves PR. Organization of the Escherichia coli K-12 gene cluster responsible for production of the extracellular polysaccharide colanic acid. J Bacteriol 1996; 178(16): 4885-93.
54. Beverley SM, Owens KL, Showalter M, et al. Eukaryotic UDPgalactopyranose mutase (GLF gene) in microbial and metazoal pathogens. Eukaryot Cell 2005; 4(6): 1147-54.
55. Kleczka B, Lamerz A-C, van Zandbergen G, et al. Targeted gene deletion of Leishmania major UDP-galactopyranose mutase leads to attenuated virulence. J Biol Chem 2007; 282(14): 10498-505.
56. Karunan Partha S, van Straaten KE, Sanders DAR. Structural basis of substrate binding to UDP-galactopyranose mutase: crystal structures in the reduced and oxidized state complexed with UDPgalactopyranose and UDP. J Mol Biol 2009; 394(5): 864-77.
57. Karunan Partha S, Sadeghi-Khomami A, Cren S, et al. Identification of novel inhibitors of UDP-galactopyranose mutase by structure-based virtual screening. Mol Inform 2011; 30(10): 873-83.
58. Beis K, Srikannathasan V, Liu H, et al. Crystal structures of Mycobacteria tuberculosis and Klebsiella pneumoniae UDPgalactopyranose mutase in the oxidised state and Klebsiella pneumoniae UDP-galactopyranose mutase in the (active) reduced state. J Mol Biol 2005; 348(4): 971-82.
59. Dhatwalia R, Singh H, Oppenheimer M, et al. Crystal structures and small-angle X-ray scattering analysis of UDP-galactopyranose mutase from the pathogenic fungus Aspergillus fumigatus. J Biol Chem 2012; 287(12): 9041-51.
60. van Straaten KE, Routier FH, Sanders DAR. Structural insight into the unique substrate binding mechanism and flavin redox state of UDP-galactopyranose mutase from Aspergillus fumigatus. J Biol Chem 2012; 287(14): 10780-90.
61. Gruber TD, Borrok MJ, Westler WM, Forest KT, Kiessling LL. Ligand binding and substrate discrimination by UDPgalactopyranose mutase. J Mol Biol 2009; 391(2): 327-40.
62. Gruber TD, Westler WM, Kiessling LL, Forest KT. X-ray crystallography reveals a reduced substrate complex of UDPgalactopyranose mutase poised for covalent catalysis by flavin. Biochemistry 2009; 48(39): 9171-3.
63. Sanders DAR, Staines AG, McMahon SA, et al. UDPgalactopyranose mutase has a novel structure and mechanism. Nat Struct Mol Biol 2001; 8(10): 858-63.
64. Oppenheimer M, Poulin MB, Lowary TL, Helm RF, Sobrado P. Characterization of recombinant UDP-galactopyranose mutase from Aspergillus fumigatus. Arch Biochem Biophys 2010; 502(1): 31-8.
65. Fraaije MW, Mattevi A. Flavoenzymes: diverse catalysts with recurrent features. Trends Biochem Sci 2000; 25(3): 126-32.
66. Massey V. The chemical and biological versatility of riboflavin. Biochem Soc Trans 2000; 28(4): 283.
67. Joosten V, van Berkel WJH. Flavoenzymes. Curr Opin Chem Biol 2007; 11(2): 195-202.
68. Barlow JN, Girvin ME, Blanchard JS. Positional isotope exchange catalyzed by UDP-galactopyranose mutase. J Am Chem Soc 1999; 121: 6968-9.
69. Fullerton SWB, Daff S, Sanders DAR, et al. Potentiometric analysis of UDP-galactopyranose mutase: stabilization of the flavosemiquinone by substrate. Biochemistry 2003; 42(7): 2104-9.
70. Huang Z, Zhang Q, Liu H-W. Reconstitution of UDP-galactopyranose mutase with 1-deaza-FAD and 5-deaza-FAD: analysis and mechanistic implications. Bioorg Chem 2003; 31(6): 494-502.
71. Soltero-Higgin M, Carlson EE, Gruber TD, Kiessling LL. A unique catalytic mechanism for UDP-galactopyranose mutase. Nat Struct Mol Biol 2004; 11(6): 539-43.
72. Sun HG, Ruszczycky MW, Chang W-C, Thibodeaux CJ, Liu H-W. Nucleophilic participation of reduced flavin coenzyme in mechanism of UDP-galactopyranose mutase. J Biol Chem 2012; 287(7): 4602-8.
73. Oppenheimer M, Valenciano AL, Kizjakina K, Qi J, Sobrado P. Chemical mechanism of UDP-galactopyranose mutase from Trypanosoma cruzi: a potential drug target against Chagas' disease. PLoS One 2012; 7(3): e32918.
74. Barlow JN, Marcinkeviciene J, Blanchard JS. The enzymatic conversion of UDP-galactopyranose to UDP-galactofuranose. Biomed Health Res 1999; 27: 98-106.
75. Köplin R, Brisson J-R, Whitfield C. UDP-galactofuranose pecursor required for formation of the lipopolysaccharide O antigen of Klebsiella pneumoniae serotype O1 is synthesized by the product of the rfbDKPO1 gene. J Biol Chem 1997; 272(7): 4121-8.
76. Persidis A. High-throughput screening. Nat Biotechnol 1998; 16(5): 488.
77. Mayr LM. Novel trends in high-throughput screening. Curr Opin Pharmacol 2009; 9(5): 580.
78. Macarrón R. Design and implementation of high throughput screening assays. Mol Biotechnol 2011; 47(3): 270-85.
79. Howe D. Big data: the future of biocuration. Nature (London) 2008; 455(7209): 47-50.
80. Bleicher KH. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2003; 2(5): 369.
81. Oprea T. Current trends in lead discovery: are we looking for the appropriate properties? J Comput Aided Mol Des 2002; 16(5): 325-34.
82. Hann MM, Oprea TI. Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 2004; 8(3): 255-63.
83. Qi J, Oppenheimer M, Sobrado P. Fluorescence polarization binding assay for Aspergillus fumigatus virulence factor UDPgalactopyranose mutase. Enzyme Res 2011; 2011.
84. Scherman MS, Winans KA, Stern RJ, et al. Drug targeting Mycobacterium tuberculosis cell wall synthesis: development of a microtiter plate-based screen for UDP-galactopyranose mutase and identification of an inhibitor from a uridine-based library. Antimicrob Agents Chemother 2003; 47(1): 378-82.
85. Carlson EE, May JF, Kiessling LL. Chemical probes of UDPgalactopyranose mutase. Chem Biol 2006; 13(8): 825-37.
86. Soltero-Higgin M, Carlson EE, Phillips JH, Kiessling LL. Identification of inhibitors for UDP-galactopyranose mutase. J Am Chem Soc 2004; 126(34): 10532-3.
87. Bohacek RS, McMartin C. Modern computational chemistry and drug discovery: structure generating programs. Curr Opin Chem Biol 1997; 1(2): 157-61.
88. Chessari G, Woodhead AJ. From fragment to clinical candidate-a historical perspective. Drug Discov Today 2009; 14(13-14): 668-75.
89. Loving K, Alberts I, Sherman W. Computational approaches for fragment-based and de novo design. Curr Top Med Chem 2010; 10: 14-32.
90. McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007; 11(5): 494-502.
91. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004; 3(11): 935-49.
92. Borrelli S, Zandberg WF, Mohan S, et al. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors. Int J Antimicrob Agents 2010; 36: 364-8.
93. Dykhuizen EC, May JF, Tongpenyai A, Kiessling LL. Inhibitors of UDP-galactopyranose mutase thwart mycobacterial growth. J Am Chem Soc 2008; 130(21): 6706-7.
94. Dutta S, Burkhardt K, Young J, et al. Data deposition and annotation at the worldwide Protein Data Bank. Mol Biotechnol 2009; 42(1): 1-13.
95. Partha SK, Sadeghi-Khomami A, Slowski K, et al. Chemoenzymatic synthesis, inhibition studies, and X-ray crystallographic analysis of the phosphono analog of UDP-Galp as an inhibitor and mechanistic probe for UDP-galactopyranose mutase. J Mol Biol 2010; 403(4): 578-90.
96. Oppenheimer M, Valenciano AL, Sobrado P. Isolation and characterization of functional Leishmania major virulence factor UDP-galactopyranose mutase. Biochem Biophys Res Commun 2011; 407(3): 552-6.
97. McMahon SA, Leonard GA, Buchanan LV, Giraud MF, Naismith JH. Initiating a crystallographic study of UDP-galactopyranose mutase from Escherichia coli. Acta Crystallogr, Sect D: Biol Crystallogr 1999; 55(2): 399-402.
98. Karunan Partha S, Bonderoff SA, van Straaten KE, Sanders DAR. Expression, purification and preliminary X-ray crystallographic analysis of UDP-galactopyranose mutase from Deinococcus radiodurans. Acta Crystallogr, Sect F: Struct Biol Cryst Commun 2009; 65(8): 843-5.
99. Zhang Q, Liu H-W. Mechanistic investigation of UDP-galactopyranose mutase from Escherichia coli using 2-and 3-fluorinated UDP-galactofuranose as probes. J Am Chem Soc 2001; 123(28): 6756-66.
100. Chad JM, Sarathy KP, Gruber TD, et al. Site-directed mutagenesis of UDP-galactopyranose mutase reveals a critical role for the active-site, conserved arginine residues. Biochemistry 2007; 46(23): 6723-32.
101. Gruber TD. Mechanism, structure and inhibition of UDP-galactopyranose mutase. The University of Wisconsin-Madison, 2009.